StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
MRKBullishEarningsnews
High materiality9/10

Merck raises 2026 guidance after Q3 beat on Keytruda and vaccines

Oct 29, 2026, 2:10 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Strong Q3 beat, raised 2026 guidance, and durable Keytruda/vaccine momentum support a near-term rally; offset by one-time acquisition charges, which are factored into the new guidance.

AI summary

What happened, with direct paths to the underlying reporting

Merck beat Q3 expectations on revenue and adjusted earnings and lifted 2026 guidance. Keytruda sales rose 6% to $8.6B, Gardasil vaccines up 14%, and Winrevair surged, collectively supporting a higher outlook and modest 2027 growth. The unwind of channel inventory is expected in Q4, potentially sustaining near-term upside.

  • Q3 adjusted EPS $2.49 vs $2.08 expected; revenue $18.085B, up 5%.
  • Keytruda sales $8.6B, up 6%; Gardasil vaccines up 14%.
  • 2026 guidance raised: adj EPS $2.77-$2.82; sales $66.80B-$67.30B.
  • Winrevair sales up 93% to $694M; stock up ~5% on the news.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event